The rabbit defect study successfully demonstrated that Vitrium was equivalent and, in some ways, superior to an FDA-approved “osteostimulative” bone graft substitute (Novabone):
1) No radiolucencies were observed in the Vitrium defects, while radiolucencies were observed in a third of the control specimens at both 8 and 16 weeks
2) Incorporation of the residual implant material within the bone was observed at 8 weeks. Healthy bone formation (black arrows) was ongoing
3) At 24 weeks, substantial trabecular bone was observed in the Vitrium defects with some residual implant still present, and greater lamellar bone formation was ongoing within the defects in amounts greater than observed with the control
4) Evidence of vascular tissue formation (black arrows) was seen at various time points in the Vitrium specimens